of the previous year. Gross profit The company has gross profit of 378.71 million baht, 264.00 million baht and 530.05 million baht in year 2018, 2019, and 2020 respectively. Gross profit margin is
results for the nine-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech
Summary Significant Event Operating Highlights in Q3/2023 Q3/22 Q3/23 Change +/(-) 9M/22 9M/23 Change +/(-) (THB million) %YoY %YoY Operating Revenue 246 338 37% 674 900 34% Gross Profit 159 223 40% 426 583
increase rate in total operating expenses in Q2- 2023 was slightly higher than the change in total revenue because projects delivered in the 2Q- 2023 has a lower gross margin than projects delivered in Q1
Limited and its subsidiaries had the operation results for the six-month period ended June, 2018 with the following details: unit: THB million 2018 2017 Change (THB million) Change (%) Revenue from Sales
Company Limited and its subsidiaries had the operation results for the nine-month period ended September 30, 2018 with the following details: unit: THB million 2018 2017 Change (THB million) Change
-Sep) operating results based on its reviewed consolidated financial statements ended September 30, 2019 as follows. Highlights on Q3-2019 Operating results Unit : Million Baht Q3-19 Q3-18 Q2-19 % Change
) Interest on margin loans 43.68 6.63 43.68 6.63 Gain and return on financial instruments 120.09 26.18 120.09 26.18 Shares of loss from investments in an associate and a joint venture (14.95) 9.70 0.00 0.00
compared to the same period last year. Table 1: Sales Revenue by Product Line for the Three Months Period Ended 31 December (YoY) Product Line/ Business Group Consolidated financial statements Change
Summary of operations and the factors that make a significant change Summary of Operations for the Year 2018 Topic Annual Balance Change 2018 2017 2018 VS 2017 (MB) (MB) % Total Revenue 4,237.6 5,397.2